Status:
SUSPENDED
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)
Lead Sponsor:
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Collaborating Sponsors:
Worldwide Clinical Trials
Conditions:
B-cell Non-Hodgkin's Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).
Eligibility Criteria
Inclusion
- 18-75 years old
- Diagnosed with B-NHL
- Relapsed after or be refractory to at least 2 line of standard therapy
Exclusion
- Active central nervous system (CNS) metastases
- Positive Direct Antiglobulin Test (DAT)
- Active autoimmune disorder
- Skin disorders that do not requires hormone replacement therapy
Key Trial Info
Start Date :
January 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 11 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04746131
Start Date
January 15 2021
End Date
April 11 2024
Last Update
September 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Christ Hospital
Cincinnati, Ohio, United States, 45219